From Jan 2024 Quarterly
"The study completed dosing as planned in December 2023. A number of animals willnow be subject to a ‘recovery period,’ designed to establish whether any effects seenwith ATL1102 administration revert to normal on cessation of treatment. The animalswill then be subject to pathological analysis to fully assess the effects of ATL1102. TheCompany expects to receive a final study report in mid-2024 and expects to discuss theresults with FDA thereafter. Successful completion of the study may allow Percheron to apply in future for special designations with FDA such as Fast Track Designation and Breakthrough Designation"
Nothing more recent has changed from that, so any time in the next couple months.
- Forums
- ASX - By Stock
- PER
- When US tox study due
When US tox study due, page-5
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
0.001(1.27%) |
Mkt cap ! $82.94M |
Open | High | Low | Value | Volume |
8.0¢ | 8.3¢ | 7.9¢ | $461.5K | 5.711M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 844186 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 292500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 844186 | 0.080 |
8 | 506274 | 0.079 |
5 | 575000 | 0.078 |
8 | 1027327 | 0.077 |
4 | 346421 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 292500 | 1 |
0.083 | 30000 | 1 |
0.084 | 93750 | 1 |
0.085 | 187500 | 2 |
0.086 | 250000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online